¡¡¡¡Ophthalmol 2006;142(6)£º961ª²969

¡¡¡¡16 Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab(Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).

¡¡¡¡Retina 2006;26(9)£º1006ª²1013

¡¡¡¡17 Modarres M, Nazari H, Falavarjani KG, et al. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy.

¡¡¡¡Eur J Ophthalmol 2009;19(5):848ª²852

¡¡¡¡18 Ahmadieh H, Shoeibi N, Entezari M, et al. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients:a randomized clinical trial. Ophthalmology 2009;116(10):1943ª²1948

¡¡¡¡19 Huang YH, Yeh PT, Chen MS, et al. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vetreous hemmorrhage. Retina 2009;29(8):1134ª²1140

¡¡¡¡20 Gonzalez VH, Giuliari GP, Banda RM, et al. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. Br J Ophthalmol 2009;93(11):1474ª²1478

¡¡¡¡21 Querques G, Bux AV, Martinelli D, et al. Intravitreal pegaptanib sodium(Macugen) for diabetic macular edema. Acta Ophthalmol 2009;87(6):623ª²630

¡¡¡¡22 Yang CM, Yeh PT, Yang CH, et al. Bevacizumab pretreatment and longª²acting gas infusion on vitreous clear up after diabetic vitrectormy.

¡¡¡¡Am J ophthalmol 2008;146(2)£º211ª²217

¡¡¡¡23 Gandhi JS, Tan LT, Pearce I, et al. Bevacizumab (Avastin) as a surgical adjunct in diabetic vitrectomy for fibrovascular disease. Eye 2009;23(3)£º742ª²743

¡¡¡¡24 Yang XL, Liu K, Xu X. Update on treatments of diabetic macular edema. Chin Med 2009;122(22):2784ª²2790

¡¡¡¡25 Soheilian M, Ramezani A, Bijanzadeh B, et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007;27(9):1187ª²1195

¡¡¡¡26 Ishida S, Usui T, Yamashiro K, et al.VEGF164ª²mediated inflammation is required for pathological, but not physiological, ischemiaª² induced retinal neovascularization. J Exp Med 2003;198(3):483ª²489

¡¡¡¡27 Mason JO 3rd, White MF, Feist RM, et al. Vail RS Incidence of acute onsetendophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008;28(54):564ª²567

¡¡¡¡28 Gragoudas ES, Adamis AP, Cunningham ET Jr, et al.VEGF inhibition study in ocular neovascularization clinical trial group pegaptanib for neovascular ageª²related macular degeneration. N Engl J Med 2004;351(27):2805ª²2816

¡¡¡¡29 D¬ðAmico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular ageª²related macular degeneration:twoª²year safety results of the two prospective, multicenter,controlled clinical trials. Ophthalmology 2006;113(6):992ª²1001

¡¡¡¡30 Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular ageª²related macular degeneration: thirdª²yearsafety results of the VEGF inhibition study in ocular neovascularisation(VISION) trial.

¡¡¡¡Br J Ophthalmol 2008;92(12):1606ª²1611

¡¡¡¡31 Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group Ranibizumab for neovascular ageª²related macular degeneration. N Engl J

¡¡¡¡Med 2006;355(14):1419ª²1431

ÉÏÒ»Ò³  [1] [2] [3] [4]